Search

Your search keyword '"Benno, Peter"' showing total 26 results
Start Over Author "Benno, Peter"
26 results on '"Benno, Peter"'

7. From IBS to DBS

Author

Benno, Peter, Dahlgren, Atti-La, Befrits, Ragnar, Norin, Elisabeth, Hellström, Per M., and Midtvedt, Tore

Subjects
irritable bowel syndrome, digestive, oral, and skin physiology, microbiota, diarrhea, Case Report, pain, dysbiosis, postinfectious IBS
Abstract

Irritable bowel syndrome is a chronic gastrointestinal disorder characterized by abdominal pain and altered bowel habits in the absence of organic disease. We present 2 cases where diarrhea-predominant irritable bowel syndrome occurred in association with earlier intestinal infection or antibiotic treatment. Both were successfully treated with instillation of an anaerobic cultivated human intestinal microbiota. Thereafter, they were symptom free for at least 12 months. We now introduce the term dysbiotic bowel syndrome covering cases where a disturbed intestinal microbiota is assumed to be present. We recommend that restoration of the dysbiotic gut microbiota should be first-line treatment in these conditions.

Published
2016

8. From IBS to DBS : The Dysbiotic Bowel Syndrome

Author

Benno, Peter, Dahlgren, Atti-La, Befrits, Ragnar, Norin, Elisabeth, Hellström, Per M., Midtvedt, Tore, Benno, Peter, Dahlgren, Atti-La, Befrits, Ragnar, Norin, Elisabeth, Hellström, Per M., and Midtvedt, Tore

Abstract

Irritable bowel syndrome is a chronic gastrointestinal disorder characterized by abdominal pain and altered bowel habits in the absence of organic disease. We present 2 cases where diarrhea-predominant irritable bowel syndrome occurred in association with earlier intestinal infection or antibiotic treatment. Both were successfully treated with instillation of an anaerobic cultivated human intestinal microbiota. Thereafter, they were symptom free for at least 12 months. We now introduce the term dysbiotic bowel syndrome covering cases where a disturbed intestinal microbiota is assumed to be present. We recommend that restoration of the dysbiotic gut microbiota should be first-line treatment in these conditions.

Published
2016
Full Text
View/download PDF

12. Biochemical parameters reflecting the intestinal ecology of healthy adults and alterations of these parameters in patients with ulcerative colitis or rheumatoid arthritis

Author

Benno, Peter and Benno, Peter

Abstract

The gastrointestinal microflora, the largest single collection of cells in the body, influence their human host in a variety of ways. Useful in this connection is the concept of Microflora-Associated Characteristics (MACs), which are defined as any anatomical structure or physiological, biochemical or immunological function in the host that is affected by the microflora. In the present investigation we have established and evaluated reliable reference values for three MACs, i.e., the conversion of cholesterol to coprostanol, content of urobilins and tryptic activity (FTA) in faecal samples. Ours is the largest study of its kind to date, assessing these parameters in more than 560 healthy men and women (HS; Healthy Subjects) and analyzing the findings with respect to both gender and age (employing arbitrary division into groups < 36, 36-50 and > 50 years old). Conversion of cholesterol to coprostanol in 633 HS; In general, the proportion of men with the highest conversion rate was found in the oldest age group in contrast to women were the conversion was of the same order of magnitude, irrespectively of age group. One possible explanation for these observations might be that men with low or no converting capacity in the oldest age group are lost in this cohort of healthy subjects. However, to rule out whether the capacity to convert cholesterol is related to morbidity requires additional long-term studies. Formation of urobilins in 562 HS; In general, the levels of urobilins were higher in men irrespectively of age group. Both bilirubin and its metabolites - urobilins - undergo enterohepatic circulation and thereby provide an interesting endogenous model for xenobiotics. The reference values found in this study might be of value when evaluating metabolism of xenobiotics in relation to gender and age. Degradation of FTA in 573 HS; In general, the mean levels were highest in the youngest male group and decreased successively in the two older groups. Although the same t

Published
2009

17. Olsalazine Versus Sulphasalazine for Relapse Prevention in Ulcerative Colitis: A Multicenter Study.

Author

Nilsson, Åke, Danielsson, Åke, Löfberg, Robert, Benno, Peter, Bergman, Lars, Fausa, Olav, Florholmen, Jon, Karvonen, Anna-Liisa, Kildebo, Stein, Kollberg, Bo, Lindberg, Greger, Lööf, Lars, Stig, Robert, and Tanghøj, Hans

Subjects
COLITIS, COLON diseases, DISEASE relapse, GASTROENTEROLOGY, DRUGS
Abstract

Objective: To compare the relapse-preventing effect and the frequency of adverse events of olsalazine and sulphasalazine in sulphasalazine-tolerant patients with ulcerative colitis. Methods: Patients in remission, with at least two episodes of active disease during the last 5 yr, were randomized to 2 g of sulphasalazine or 1 g of olsalazine daily and were followed for 6-18 months. Relapse rates in the two groups were compared using frequency and life-table analysis. Sixty-nine patients with proctitis, 140 with left-sided colitis, and 113 with subtotal or total colitis were evaluated. Results: In the intention-to-treat analysis, the failure rate (relapses plus withdrawals) was 54.7% in the olsalazine and 47.2% in the sulphasalazine group. In the per-protocol analysis excluding withdrawals, 44.7% relapsed in the olsalazine and 39.3% in the sulphasalazine group. Remission curves did not differ significantly, although at all time intervals the frequency of remission was slightly higher in the sulphasalazine group (p = 0.19 in the intention-to-treat analysis and p = 0.42 in the per-protocol analysis estimated by the log-rank test). Twelve patients (of whom five had diarrhea) in the olsalazine group versus eight patients in the sulphasalazine group discontinued the study because of side effects. Conclusion: The relapse-preventing effect of olsalazine and sulphasalazine in sulphasalazine-tolerant patients did not differ. Furthermore, the tolerability of olsalazine, particularly concerning diarrhea, appears to be better than previously reported. [ABSTRACT FROM AUTHOR]

Published
1995

19. [Underlying dysbiosis may be the cause of some forms of IBS. Patients were free of symptoms after the administration of microbiota].

Author

Benno P, Befrits R, Berstad A, Dahlgren AL, Norin E, and Midtvedt T

Subjects
Adult, Biological Therapy methods, Feces microbiology, Female, Humans, Male, Microbiota, Transplantation methods, Dysbiosis complications, Irritable Bowel Syndrome microbiology
Abstract

Two cases of post-infectious IBS were successfully treated with transplantation of an anaerobic cultivated human intestinal microbiota. This suggests that a dysbiosis of the intestinal microbiota could be the culprit at least in some cases of IBS. Resetting the gut microbiota might be a possible solution for these patients that otherwise may face a life-long reduction in quality of life. Studies have suggested that conditions as varied as chronic constipation, metabolic syndrome, autoimmunity, asthma, cardiovascular disease and Crohn's disease may be caused by intestinal dysbiosis. If this is the case we would like to suggest a new term: Dysbiotic Bowel Syndrome (DBS).

Published
2015

20. [Clostridium difficile--unfairly set in the corner?].

Author

Benno P, Dahlgren AL, Norin E, and Midtvedt T

Subjects
Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents therapeutic use, Bacteriological Techniques methods, Biological Therapy methods, Diarrhea microbiology, Diarrhea therapy, Enterocolitis, Pseudomembranous microbiology, Feces microbiology, Humans, Intestines microbiology, Metagenome, Clostridioides difficile isolation & purification, Enterocolitis, Pseudomembranous therapy
Published
2012

22. [Helicobacter pylori--a friend in need].

Author

Benno P, Dahlgren AL, and Midtvedt T

Subjects
Animals, Biological Evolution, Dietary Proteins metabolism, Ecosystem, Helicobacter pylori metabolism, Humans, Nitrogen metabolism, Nitrogen physiology, Stomach microbiology, Urea metabolism, Helicobacter pylori physiology
Published
2011

23. [Prebiotics is food for the intestinal flora--for good and bad].

Author

Benno P, Midtvedt T, Norin E, and Zachrisson K

Subjects
Bacteria growth & development, Bacteria metabolism, Colon microbiology, Fermentation, Humans, Intestinal Absorption, Dietary Fiber administration & dosage, Dietary Fiber adverse effects, Irritable Bowel Syndrome diet therapy, Irritable Bowel Syndrome etiology, Irritable Bowel Syndrome microbiology, Prebiotics adverse effects
Published
2010

24. [Probiotics--friends or enemies of the intestine?].

Author

Benno P, Ernberg I, Midtvedt T, Norin E, and Zachrisson K

Subjects
Colonic Neoplasms microbiology, Colonic Neoplasms prevention & control, Diarrhea microbiology, Diarrhea prevention & control, Diarrhea therapy, Evidence-Based Medicine, Humans, Hypersensitivity microbiology, Hypersensitivity prevention & control, Intestinal Diseases microbiology, Intestinal Diseases prevention & control, Intestinal Diseases therapy, Intestines microbiology, Treatment Outcome, Probiotics adverse effects, Probiotics therapeutic use
Published
2010

25. [Intestinal flora--the biggest organ of the body. Unstable ecosystem which can easily topple].

Author

Benno P, Blomquist L, Ernberg I, Midtvedt T, Möllby R, and Norin E

Subjects
Animals, Germ-Free Life, Humans, Infant, Newborn, Intestinal Absorption physiology, Intestinal Diseases metabolism, Intestinal Diseases microbiology, Intestinal Diseases therapy, Intestinal Mucosa metabolism, Intestinal Mucosa microbiology, Microbial Viability, Bacteria growth & development, Bacteria metabolism, Bacteria pathogenicity, Ecosystem, Intestines microbiology
Published
2010

26. [Should we load the dosette with anti-cirrhotic pills?].

Author

Benno P

Subjects
Extracellular Matrix Proteins genetics, Fatty Liver complications, Fatty Liver etiology, Humans, Liver Cirrhosis etiology, Liver Cirrhosis genetics, Obesity complications, Liver Cirrhosis prevention & control
Published
2006

Catalog

Books, media, physical & digital resources
See catalog results